COvid-19 and high-dose VITamin D supplementation TRIAL in high-risk older patients (COVIT-TRIAL): study protocol for a randomized controlled trial DOI Creative Commons
Cédric Annweiler, Mélinda Beaudenon, Jennifer Gautier

et al.

Trials, Journal Year: 2020, Volume and Issue: 21(1)

Published: Dec. 28, 2020

Abstract Background With the lack of effective therapy, chemoprevention, and vaccination against SARS-CoV-2, focusing on immediate repurposing existing drugs gives hope curbing COVID-19 pandemic. A recent unbiased genomics-guided tracing SARS-CoV-2 targets in human cells identified vitamin D among three top-scoring molecules manifesting potential infection mitigation patterns. Growing pre-clinical epidemiological observational data support this assumption. We hypothesized that supplementation may improve prognosis COVID-19. The aim trial is to compare effect a single oral high dose cholecalciferol versus standard all-cause 14-day mortality rate older adults at higher risk worsening. Methods COVIT-TRIAL study an open-label, multicenter, randomized controlled superiority trial. Patients aged ≥ 65 years with (diagnosed within preceding 3 days RT-PCR and/or chest CT scan) least one worsening factor time inclusion (i.e., age 75 years, or SpO2 ≤ 94% room air, PaO2/FiO2 300 mmHg), having no contraindications supplementation, received > 800 IU/day during month are recruited. Participants either high-dose (two 200,000 IU drinking vials once day inclusion) standard-dose (one 50,000 vial inclusion). Two hundred sixty participants recruited followed up for 28 days. primary outcome measure 14 inclusion. Secondary outcomes score changes World Health Organization Ordinal Scale Clinical Improvement (OSCI) scale COVID-19, between-group comparison safety. These assessed baseline, 14, 28, together serum concentrations 25(OH)D, creatinine, calcium, albumin baseline 7. Discussion our knowledge first testing high-risk patients. High-dose be effective, well-tolerated, easily immediately accessible treatment incidence which increases dramatically there currently scientifically validated treatments. Trial registration ClinicalTrials.gov NCT04344041 . Registered April 2020 status Recruiting. Recruitment expected completed 2021.

Language: Английский

Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19 DOI Open Access
Igor Hisashi Murai, Alan Lins Fernandes, Lucas Peixoto Sales

et al.

JAMA, Journal Year: 2021, Volume and Issue: 325(11), P. 1053 - 1053

Published: Feb. 20, 2021

The efficacy of vitamin D3 supplementation in coronavirus disease 2019 (COVID-19) remains unclear.To investigate the effect a single high dose on hospital length stay patients with COVID-19.This was multicenter, double-blind, randomized, placebo-controlled trial conducted 2 sites Sao Paulo, Brazil. study included 240 hospitalized COVID-19 who were moderately to severely ill at time enrollment from June 2, 2020, August 27, 2020. final follow-up October 7, 2020.Patients randomly assigned receive oral 200 000 IU (n = 120) or placebo 120).The primary outcome stay, defined as date randomization discharge. Prespecified secondary outcomes mortality during hospitalization; number admitted intensive care unit; required mechanical ventilation and duration ventilation; serum levels 25-hydroxyvitamin D, total calcium, creatinine, C-reactive protein.Of randomized patients, 237 analysis (mean [SD] age, 56.2 [14.4] years; 104 [43.9%] women; mean baseline D level, 20.9 [9.2] ng/mL). Median (interquartile range) not significantly different between (7.0 [4.0-10.0] days) groups [5.0-13.0] (log-rank P .59; unadjusted hazard ratio for discharge, 1.07 [95% CI, 0.82-1.39]; .62). difference group significant in-hospital (7.6% vs 5.1%; difference, 2.5% -4.1% 9.2%]; .43), admission unit (16.0% 21.2%; -5.2% -15.1% 4.7%]; .30), need 14.4%; -6.8% 1.2%]; .09). Mean increased after (44.4 ng/mL 19.8 ng/mL; 24.1 19.5-28.7]; < .001). There no adverse events, but an episode vomiting associated intervention.Among COVID-19, D3, compared placebo, did reduce stay. findings do support use treatment moderate severe COVID-19.ClinicalTrials.gov Identifier: NCT04449718.

Language: Английский

Citations

457
The link between COVID-19 and VItamin D (VIVID): A systematic review and meta-analysis DOI Creative Commons
Aya Bassatne, Maya Basbous, Marlene Chakhtoura

et al.

Metabolism, Journal Year: 2021, Volume and Issue: 119, P. 154753 - 154753

Published: March 24, 2021

Disease severity and mortality rates due to COVID-19 infection are greater in the elderly chronically ill patients, populations at high risk for vitamin D deficiency. Vitamin plays an important role immune function inflammation. This systematic review meta-analysis assesses impact of status supplementation on related health outcomes.

Language: Английский

Citations

202
Effects of a 2-Week 5000 IU versus 1000 IU Vitamin D3 Supplementation on Recovery of Symptoms in Patients with Mild to Moderate Covid-19: A Randomized Clinical Trial DOI Open Access
Shaun Sabico, Mushira A. Enani, Eman Sheshah

et al.

Nutrients, Journal Year: 2021, Volume and Issue: 13(7), P. 2170 - 2170

Published: June 24, 2021

Objective: Vitamin D deficiency has been associated with an increased risk of COVID-19 severity. This multi-center randomized clinical trial aims to determine the effects 5000 IU versus 1000 daily oral vitamin D3 supplementation in recovery symptoms and other parameters among mild moderate patients sub-optimal status. Study Design Setting: A total 69 reverse transcriptase polymerase chain reaction (RT-PCR) SARS-CoV-2 positive adults who were hospitalized for disease allocated receive once 2 weeks either (n = 36, 21 males; 15 females) or (standard control) 33, 13 20 females). Anthropometrics measured blood samples taken pre- post-supplementation. Fasting glucose, lipids, serum 25(OH)D, inflammatory markers measured. noted on admission monitored until full recovery. Results: caused a significant increase 25(OH)D levels group only (adjusted p 0.003). Within-group comparisons also showed decrease BMI IL-6 overtime both groups (p-values < 0.05) but was not clinically between-group comparisons. Kaplan–Meier survival analysis revealed that had significantly shorter time (days) than resolving cough, even after adjusting age, sex, baseline BMI, D-dimer (6.2 ± 0.8 9.1 0.8; 0.039), ageusia (loss taste) (11.4 1.0 16.9 1.7; 0.035). Conclusion: reduces cough gustatory sensory loss status symptoms. The use as adjuvant therapy suboptimal status, short duration, is recommended.

Language: Английский

Citations

176
Vitamin D Status and SARS-CoV-2 Infection and COVID-19 Clinical Outcomes DOI Creative Commons
Iacopo Chiodini, Davide Gatti, Davide Soranna

et al.

Frontiers in Public Health, Journal Year: 2021, Volume and Issue: 9

Published: Dec. 22, 2021

Background: Several studies suggest an association between serum 25-hydroxyvitamin D (25OHD) and the outcomes of Severe Acute Respiratory Syndrome Corona-Virus-2 (SARS-CoV-2) infection, in particular Coronavirus Disease-2019 (COVID-19) related severity mortality. The aim present meta-analysis was to investigate whether vitamin status is associated with COVID-19 severity, defined as ARDS requiring admission intensive care unit (ICU) or mortality (primary endpoints) susceptibility SARS-CoV-2 COVID-19-related hospitalization (secondary endpoints). Methods: A search PubMed, ScienceDirect, Web Science, Google Scholar, Scopus, preprints repositories performed until March 31th 2021 identify all original observational reporting measures, enough data calculate them, Vitamin (insufficiency &lt;75, deficiency &lt;50, severe &lt;25 nmol/L) risk hospitalization, ICU admission, death during hospitalization. Findings: Fifty-four (49 fully-printed 5 pre-print publications) were included for a total 1,403,715 individuals. SARS-CoV2 reported 17, 9, 27, 35 studies, respectively. deficiency, insufficiency (odds ratio [OR], 95% confidence intervals [95%CIs]: 2.63, 1.45–4.77; 2.16, 1.43–3.26; 2.83, 1.74–4.61, respectively), (OR, 95%CIs: 2.60, 1.93–3.49; 1.84, 1.26–2.69; 4.15, 1.76–9.77, infection 1.68, 1.32–2.13; 1.83, 1.43–2.33; 1.49, 1.16–1.91, respectively) 95%CIs 2.51, 1.63–3.85; 2.38, 1.56–3.63; 1.82, 1.43–2.33). Considering specific subgroups (i.e., Caucasian patients, high quality adjusted estimates) results primary endpoints did not change. Interpretations: Patients low levels increased due higher

Language: Английский

Citations

152
Retracted: COVID‐19 mortality and its predictors in the elderly: A systematic review DOI
Omid Dadras, SeyedAhmad SeyedAlinaghi, Amirali Karimi

et al.

Health Science Reports, Journal Year: 2022, Volume and Issue: 5(3)

Published: May 1, 2022

Abstract Background and Aims Older people have higher rates of comorbidities may experience more severe inflammatory responses; therefore, are at risk death. Herein, we aimed to systematically review the mortality in coronavirus disease 2019 (COVID‐19) patients its predictors this age group. Methods We searched PubMed, Web Science, Science Direct using relevant keywords. Retrieved records underwent a two‐step screening process consisting title/abstract full‐text screenings identify eligible studies. Results Summarizing findings 35 studies demonstrated that older compared younger population. A articles revealed increasing age, body mass index, male gender, dementia, impairment or dependency daily activities, presence consolidations on chest X‐ray, hypoxemic respiratory failure, lower oxygen saturation admission were factors for High d ‐dimer levels, 25‐hydroxy vitamin D serum deficiencies, high C‐reactive protein (≥5 mg/L) levels plus any other abnormalities lymphocyte, blood urea nitrogen lactate dehydrogenase, platelet count poor prognosis elderly. Studies also shown previous treatment with renin–angiotensin–aldosterone system inhibitors, pharmacological treatments disorders, antibiotics, corticosteroids, K antagonist, antihistamines, azithromycin, Itolizumab (an anti‐CD6 monoclonal antibody) combination antivirals reduces COVID‐19 worsening mortality. Vaccination against seasonal influenza might reduce Conclusion Overall, critical consideration is necessary care management aged population considering drastic contrasts manifestation groups. Mortality from independently associated patient's age. Elderly vulnerable outcomes. Thus, strict preventive measures, timely diagnosis, aggressive therapeutic/nontherapeutic great importance acute distress syndrome complications people.

Language: Английский

Citations

131
Association of Vitamin D Status with SARS-CoV-2 Infection or COVID-19 Severity: A Systematic Review and Meta-analysis DOI Creative Commons
Asma Kazemi,

Vida Mohammadi,

Sahar Keshtkar Aghababaee

et al.

Advances in Nutrition, Journal Year: 2021, Volume and Issue: 12(5), P. 1636 - 1658

Published: Jan. 22, 2021

Language: Английский

Citations

127
Vitamin D supplementation and clinical outcomes in COVID-19: a systematic review and meta-analysis DOI Creative Commons
Rimesh Pal, Mainak Banerjee, Sanjay Kumar Bhadada

et al.

Journal of Endocrinological Investigation, Journal Year: 2021, Volume and Issue: 45(1), P. 53 - 68

Published: June 24, 2021

Language: Английский

Citations

114
Vitamin D supplementation and COVID-19 risk: a population-based, cohort study DOI Creative Commons
J. Oristrell, Joan Carles Oliva, E. Casado

et al.

Journal of Endocrinological Investigation, Journal Year: 2021, Volume and Issue: 45(1), P. 167 - 179

Published: July 17, 2021

Language: Английский

Citations

110
Association of vitamin D status with COVID-19 and its severity DOI Open Access
Jae Hyun Bae, Hun Jee Choe, Michael F. Holick

et al.

Reviews in Endocrine and Metabolic Disorders, Journal Year: 2022, Volume and Issue: 23(3), P. 579 - 599

Published: Jan. 4, 2022

Language: Английский

Citations

78
Effects of Vitamin D Supplementation on COVID-19 Related Outcomes: A Systematic Review and Meta-Analysis DOI Open Access

Banafsheh Hosseini,

Asmae El, Francine M. Ducharme

et al.

Nutrients, Journal Year: 2022, Volume and Issue: 14(10), P. 2134 - 2134

Published: May 20, 2022

The COVID-19 outbreak has rapidly expanded to a global pandemic; however, our knowledge is limited with regards the protective factors against this infection. aim of systematic literature review and meta-analysis was evaluate impact vitamin D supplementation on related outcomes. A search relevant papers published until January 2022 conducted identify randomized controlled trials (RCTs) non-randomized studies intervention (NRISs). primary outcomes included risk infection (primary prevention uninfected individuals), hospital admission (secondary mild cases), ICU mortality rate (tertiary hospitalized patients). We identified five (one RCT, four NRISs) prevention, (two RCTs, three secondary 13 (six seven tertiary prevention. Pooled analysis showed no significant effect No possible hospitalization due paucity data. Vitamin significantly associated reduced (RR = 0.35, 95% CI: 0.20, 0.62) 0.46, 0.30, 0.70). had infection, whereas it effects in patients.

Language: Английский

Citations

77